Posted by Michael Wonder on 19 Dec 2024
MAIA Biotechnology granted FDA rare paediatric disease designation for THIO as a treatment for paediatric high grade gliomas
16 December 2024 - MAIA Biotechnology today announced that the FDA has designated THIO for the treatment of pediatric-type diffuse high grade gliomas as a drug for a rare paediatric disease.
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first in class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer.
